Millions take fish oil for the brain, and a two-year trial found it did nothing for memory

A two-year randomized trial of 365 older adults found that a high daily dose of fish oil reached the brain and still did nothing measurable for memory. The supplement supplied 2,000 milligrams of the omega-3 fat DHA, and after two years the group taking it performed no better on memory and thinking tests than the group given a placebo. Lead researcher Hussein Naji Yassine of the University of Southern California said the findings showed that fish oil supplements do not appear to protect brain health.

Stay ahead on AI: Join 600,000+ professionals who read The Deep View, the daily newsletter that keeps you up to date with artificial intelligence.

Subscribe to The Deep View →

We may earn a commission if you sign up.

The result matters because the market is large. ScienceDaily’s account of the study says Americans spend more than $1 billion a year on omega-3 supplements, and a good share of that money is spent in the hope of protecting memory. That spending figure is the news service’s, not the paper’s, and the trial did not measure how many people take fish oil for the brain.

A 365-person trial built to test the brain, not the blood

The paper, “CNS target engagement of high-dose DHA supplementation in older adults at risk for dementia: a randomised, double-blind, placebo-controlled trial,” appeared in eBioMedicine (2026; volume 129, article 106316). It has no acronym or catchy name; its name describes a design aimed at central nervous system target engagement, meaning it first asked whether supplemental DHA gets into the brain’s environment at all. Yassine directs the USC Center for Personalized Brain Health at Keck Medicine of USC, and 18 co-authors, including Lon Schneider and Naoko Kono, share the byline.

Participants were 365 adults aged 55 to 80 who rarely ate fish and carried an elevated risk of Alzheimer’s disease; about 47% were carriers of the APOE4 gene variant, the strongest common genetic risk factor. None had serious memory problems at the start, but each had at least one dementia risk factor such as obesity, high blood pressure or inactivity, according to coverage on ALZinfo. They took either the DHA supplement or a lookalike placebo pill daily, and testing was repeated at the two-year mark.

Funding came mainly from the National Institutes of Health, through six grants including RF1AG076124 and R01AG055770, plus a grant from the Alzheimer’s Drug Discovery Foundation. The intervention was a daily fish oil supplement supplying 2,000 mg of DHA, one of the two main omega-3 fats in fish oil, which is why the paper frames its question around DHA specifically rather than fish oil in general. A randomized, double-blind design means neither participants nor staff knew who received the supplement until the data were analyzed, the standard safeguard against expectation shaping results on subjective memory tests.

Cerebrospinal fluid shifted; the memory tests did not

The delivery question has a clear answer. At six months, DHA in the participants’ cerebrospinal fluid, the liquid that bathes the brain and spinal cord, had risen by an average of 17% in the supplement group. The omega-3s were getting where the theory said they needed to go, and the 17% rise is the measure the trial’s title calls target engagement. That is why the null result carries weight: the usual excuse for a failed supplement trial, that too little of the compound reached its target, does not apply here.

The outcomes that mattered did not follow. After two years, the supplement group did no better than placebo on memory and thinking tests, and brain scans showed the supplement did not prevent shrinkage of the hippocampus, the memory-related region where Alzheimer’s damage tends to begin. ALZinfo reported no benefit in the APOE4 carriers either. The accessible summaries do not give test scores, effect sizes or confidence intervals, and they do not state which outcome the investigators had designated primary, so those details sit in the full paper.

The research team’s own framing is a negative finding: the results, Yassine said, do not support fish oil supplements as a preventive measure against Alzheimer’s. The study has been picked up by health-news syndicators since its June publication, for example in a pharmacy health-library item in a write-up calling the supplements a bust for Alzheimer’s prevention.

The limits of a two-year trial

The authors are careful about scope. Only high-dose DHA was tested, so the trial says nothing about other omega-3s such as EPA or about lower doses. The volunteers were at elevated risk and rarely ate fish, and results could differ in people with different diets or in people who already have symptoms. Coverage also noted that benefits from a varied, nutrient-rich diet might build over longer than two years, a point the trial could not address.

The researchers offer a hypothesis, still under investigation, for why eating well might do what a capsule cannot: that the Mediterranean-style pattern of foods works through many nutrients and habits together. Yassine compared a healthy lifestyle to regular car maintenance for the brain, and said staying healthy throughout life remains the most powerful tool for reducing Alzheimer’s risk. Lifestyle factors such as exercise, sleep and diet were not directly tested in this trial, so that remains an interpretation rather than a result.

The brief ScienceDaily item that carried the finding, listed in its top science feed on Oct. 22, ended on the same note, that diet may offer benefits supplements cannot. The full ScienceDaily release is dated Oct. 20, but the journal article and the first coverage predate it: ALZinfo gives the eBioMedicine publication date as June 18, 2026.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

Stay ahead on AI: Subscribe to The Deep View →

We may earn a commission if you sign up.